Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CERo anticipates initiating clinical trials for its lead product candidate, CER-1236. Currently, it is being evaluated on the IND enabling stage for the treatment of Acute Myeloid Leukemia.
Lead Product(s): CER-1236
Therapeutic Area: Oncology Product Name: CER-1236
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
CERo’s technology aims to expand the therapeutic potential of CER T cell engineered-based therapies by introducing distinct and complementary tumor cell clearance pathways into a single T cell.
Lead Product(s): CER T-cell Therapy,Olaparib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022